Therapeutic Approach Developed by CSC Scientific Advisory Board Members...
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis Princeton, NJ – May 12, 2008 Medarex, Inc. (Nasdaq: MEDX) announced today that...
View ArticleALS Therapy Development Institute and California Stem Cell, Inc. Announce...
Bi-coastal collaboration aimed at applying stem cell technology to an “orphan disease” in a unique translational research setting Cambridge, Mass. & Irvine, Calif – July 29, 2008 ALS Therapy...
View ArticleFamilies of Spinal Muscular Atrophy Funded Stem Cell Motor Neuron Replacement...
FSMA has invested $1.5 Million to develop a motor neuron replacement therapy for SMA, resulting in significant progress. Libertyville, Ill., December 30, 2008 FSMA has invested significant resources in...
View ArticleFamilies of Spinal Muscular Atrophy and California Stem Cell Announce...
Funding Awarded from The Dhont Family Foundation to Families of Spinal Muscular Atrophy for $180,000 to Achieve Submission of Investigational New Drug (IND) Application to the FDA. Libertyville, Ill.,...
View ArticleTherapeutic Approach Developed by CSC Scientific Advisory Board Members...
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis PRINCETON, N.J., May 14, 2009 Medarex, Inc. (Nasdaq: MEDX) today announced that the...
View ArticleCalifornia Stem Cell, Inc. and Families of Spinal Muscular Atrophy Announce...
Significant Progress made Towards Moving Novel Therapy into Human Clinical Trials IRVINE, Calif. (October 14, 2009) California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA)...
View ArticleStem Cell Based Treatment for Spinal Muscular Atrophy Receives Orphan Drug...
California Stem Cell, Inc And Families Of Spinal Muscular Atrophy Reach Significant Milestone In Development Of Motor Neuron Treatment For SMA IRVINE, Calif. (December 7, 2009) California Stem Cell,...
View ArticleCalifornia Stem Cell, Inc. Closes Series B Financing Round
Investment to Enable Advancement of Therapeutic and Commercial Aims IRVINE, Calif. (December 21, 2009) California Stem Cell, Inc. (CSC), a leading stem cell company, announced that it has completed a...
View ArticleCalifornia Stem Cell and ALS Therapy Development Institute Extend Their...
Collaboration will further evaluate novel stem cell-derived product for the treatment of fatal neurodegenerative disease by regulating genes relevant to disease progression CAMBRIDGE, Mass. &...
View ArticleCalifornia Stem Cell SAB Chairman Hans Keirstead Wins 2010 Mathilde Solowey...
Prestigious award given for outstanding work in the field of neuroscience. IRVINE, Calif. (February 25, 2010) UC Irvine neurobiologist Hans S. Keirstead has been named the winner of the prestigious...
View ArticleCSC Scientist Receives Lloyd Guth Award For Excellence In Graduate Research...
Dr. Monica Siegenthaler lauded for her work in age-associated myelin pathogenesis and exercise attenuating functional deficits following spinal cord injury. IRVINE, Calif. (May 24, 2010) CSC Scientist...
View ArticleCalifornia Stem Cell Leaders Keirstead and Airriess Panelists at Advocacy and...
Hans S. Keirstead, Ph.D. and Chris N. Airriess, Ph.D. to speak at two significant advocacy and academic conferences this week: The Families of Spinal Muscular Atrophy (FSMA) Conference June 23 – 26 and...
View ArticleCalifornia Stem Cell Leaders Keirstead and Airriess Scheduled to Speak at...
Hans S. Keirstead, Ph.D. and Chris Airriess, Ph.D. scheduled to address four prominent stem cell conferences in coming weeks. IRVINE, Calif. (September 13, 2011) California Stem Cell, Inc. (CSC)’s Hans...
View ArticleCalifornia Stem Cell Acquires Cancer Stem Cell Therapy Program
California Stem Cell, Inc. expands therapeutics program to include a cell therapy for malignant melanoma. IRVINE, Calif. (October 25, 2011) California Stem Cell (CSC) announced today that it has...
View ArticleCalifornia Stem Cell’s Hans S. Keirstead, Ph.D. One of Six Leading Innovators...
IRVINE, Calif. (November 02, 2011) California Stem Cell (CSC)’s Hans S. Keirstead, Ph.D., has recently been recognized as one of the top innovators in global health. This praise came in an article by...
View ArticleCalifornia Stem Cell’s Hans Keirstead Weighs in on Geron News
IRVINE, Calif. (November 15, 2011) California Stem Cell, Inc. (CSC) announced today that despite recent financial setbacks at Geron Corp., CSC’s own stem cell therapeutic programs remain financially...
View ArticleIndustry Consultant Gregory Bonfiglio Joins California Stem Cell Board of...
IRVINE, Calif. (May 17, 2012) California Stem Cell, Inc. (CSC) announced today that well-known stem cell & regenerative medicine industry veteran Gregory A. Bonfiglio, J.D. has joined its Board of...
View ArticleCalifornia Stem Cell Medical Director Robert O. Dillman, M.D. to Present...
IRVINE, Calif. (June 27, 2012) Concluding a series of conference presentations in recent months, California Stem Cell (CSC) Medical Director and Principal Investigator Robert O. Dillman, M.D. will be...
View ArticleCalifornia Stem Cell Scientific Advisory Board Chairman Hans Keirstead To...
IRVINE, Calif. (September 19, 2012) California Stem Cell, Inc. (CSC) scientific advisory board chairman Hans S. Keirstead, Ph.D. will be among a notable group forward-thinking innovators, designers,...
View ArticleCalifornia Stem Cell Cancer Researchers Scheduled To Present At Upcoming...
IRVINE, Calif. (October 22, 2012) — California Stem Cell, Inc. (CSC)’s Andrew Cornforth, Ph.D. and Robert Dillman, M.D. are scheduled to speak at two prominent immunology conferences this week. The...
View ArticleCalifornia Stem Cell Submits FDA Phase III Clinical Trial Protocol For The...
IRVINE, Calif. (July 26, 2013)California Stem Cell, Inc. (“CSC”) announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration (“FDA”) for a randomized, double-blind...
View ArticleCancer Immunotherapy Platform Targets Broad Range Of Metastatic Cancers
– California Stem Cell Inc.’s Process Potentially Applicable to Several Solid Tumor Cancers –IRVINE, Calif. (July 31, 2013) — California Stem Cell, Inc. (CSC) has announced the completion of an...
View ArticleAdvanced Melanoma Patients’ Long-Term Survival Improved With California Stem...
– Phase II Data Comparing IL-2 and DC-TC Patients Presented at SITC 2013 Meeting – IRVINE, Calif. (November 12, 2013) — Advanced melanoma patients who received an experimental patient-specific tumor...
View ArticleCalifornia Stem Cell Announces U.S. FDA Approval Of Phase III Cancer Stem...
– Go-Ahead Received for Stem Cell-Based Therapy to Explore its Potential to Treat the Deadliest Form of Skin Cancer –IRVINE, Calif. (December 3, 2013) — California Stem Cell, Inc. (CSC) announced today...
View ArticleCalifornia Stem Cell Announces Completion Of Phase I Cancer Stem Cell...
IRVINE, Calif. (December 18, 2013) — California Stem Cell, Inc. (CSC) announced today the successful completion of a Phase I clinical trial investigating the safety of a cancer stem cell-based therapy...
View ArticleCalifornia Stem Cell Submits Phase II Clinical Trial Protocol To FDA For...
IRVINE, Calif. (January 23, 2014) — California Stem Cell, Inc. (“CSC”) announced today it has submitted a Phase II protocol to the U.S. Food and Drug Administration for a randomized, double-blind study...
View ArticleCalifornia Stem Cell Partners on CIRM Grant to Develop Transplantable 3D Retinas
IRVINE, Calif. (February 6, 2014) — California Stem Cell, Inc. (“CSC”) announced today the initiation of a collaborative study with the University of California, Irvine (UCI) aimed to create...
View ArticleCalifornia Stem Cell Announces U.S. FDA Approval Of Phase II Cancer Stem Cell...
– Go-Ahead Received for Stem Cell-Based Therapy to Explore its Potential to Treat Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma –IRVINE, Calif. (February 18, 2014) — California...
View ArticleNeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.
Addition of a Phase 3 ready immunotherapy targeting the cancer initiating cells for melanomaNEW YORK, April 14, 2014 — NeoStem, Inc. (NASDAQ:NBS) (“NeoStem” or the “Company”), a leader in the emerging...
View Article
More Pages to Explore .....